Group 4G: HR+ Breast Cancer; Hormone Therapies; Real-World Data/Outcomes; Targeted Therapies
Thursday, June 15
10:00 am – 11:30 am Eastern Time (US/New York)
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis
Poster author Stephanie Graff, M.D. is also the scientist for this session
Scientist: Stephanie Graff, M.D.
Stephanie L. Graff is the Director of the Breast Oncology Program at Lifespan Cancer Institute, and co-leader of the Breast Cancer Translational Research Disease Group. In addition, she serves as a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research. She is active across numerous professional organizations in oncology, including the American Society of Clinical Oncology (ASCO) where she is a 2020 graduate of the prestigious Leadership Development Program and currently serves on the Joint Certifications Committee; the Rhode Island Leadership Council for the American Cancer Society; the Breast Cancer Committee for the Alliance for Clinical Trials in Oncology cooperative group; and is on the Health Disparities Council for the Caris Precision Oncology Alliance (POA) and is chair-elect for the Breast Disease group of the Caris POA. Dr. Graff is a leader on social media and a sought-after public speaker.
Research Interests include oncology drug development and clinical trials, the breast microbiome, breast cancer genomics, health disparities, women in medicine, and rare breast cancers including male breast cancer, pregnancy-associated breast cancer, pre-menopausal breast cancer, among others.